On October 9, 2026, targeted drugs known as menin inhibitors were in clinical use for certain genetic subtypes of acute myeloid leukaemia (AML), with research groups — including teams at Dana-Farber — testing whether combinations can turn early responses into durable remissions.
AML is not one disease. It is a family of blood cancers distinguished by the mutations driving them, and treatment is increasingly chosen by molecular profile rather than by microscope appearance alone. Menin inhibitors attack one such driver: the interaction between the menin protein and the KMT2A (MLL) gene machinery, which in KMT2A-rearranged leukaemia — and, it has emerged, in leukaemia carrying NPM1 mutations — locks blood cells in an immature, proliferating state. Block that interaction and, in responsive patients, malignant cells can be pushed to mature and die. The first drug of the class reached patients after showing it could clear disease in some heavily pre-treated cases where chemotherapy had little left to offer.
Single-agent success in leukaemia, however, usually proves temporary; resistant clones find other routes. That is why the field’s centre of gravity has moved to combinations — pairing menin inhibition with established agents such as venetoclax-based regimens or conventional chemotherapy, and testing the drugs earlier in the disease course rather than only after relapse. According to the researchers involved, the questions are now practical ones: which mutations predict response, how resistance emerges, and whether combination toxicity stays manageable in older, frailer patients who make up much of the AML population.
A broader shift in blood-cancer care
The menin story is one front in a wider change. Where AML care once meant variations on intensive chemotherapy for those fit enough to survive it, molecular testing at diagnosis now routes patients toward targeted pills, antibody therapies and gentler combinations matched to their cancer’s wiring. Combination trials will decide whether menin inhibitors become a durable pillar of that new architecture or a bridge therapy of narrower use — the difference, for patients, between a temporary response and years of remission.
GlobeNews9’s Health & Science Desk will follow the combination trial readouts as they are reported.
Related reading: A Break From Training Costs Fitness Faster Than Many Expect · France's Pink October Turns Breast Cancer Screening Into a National Reminder · Protein Hype Meets a Simpler Nutrition Test
